Last 36 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -47.57 | 55.93 | 54.39 | — | — | 160.81 | 20.19 | — | 5.03 | — | 63.10 | — | — | — | 11.19 | — | — | — | 65.22 | — | — |
| — | -65.2% | +169.3% | — | — | — | -68.0% | — | — | — | +463.9% | — | — | — | -82.8% | — | — | — | — | — | — | |
| P/S Ratio | 2.37 | 2.28 | 2.21 | 2.46 | 2.20 | 1.44 | 1.10 | 1.47 | 1.77 | 1.51 | 1.68 | 1.77 | 1.30 | 1.17 | 0.92 | 1.51 | 1.48 | 2.04 | 2.62 | 3.11 | 3.44 |
| — | +58.2% | +101.1% | +67.5% | +24.0% | -4.5% | -34.4% | -17.3% | +36.9% | +28.5% | +81.8% | +17.4% | -12.2% | -42.5% | -64.8% | -51.4% | -57.0% | -38.3% | -9.2% | -5.0% | -5.4% | |
| P/B Ratio | 1.70 | 1.89 | 1.86 | 1.72 | 1.48 | 1.05 | 0.82 | 0.98 | 1.12 | 1.20 | 1.33 | 1.18 | 0.90 | 0.67 | 0.62 | 0.82 | 0.90 | 1.34 | 1.69 | 1.84 | 2.02 |
| — | +79.3% | +125.8% | +74.9% | +32.3% | -12.2% | -38.1% | -16.8% | +24.1% | +79.7% | +115.3% | +44.1% | +0.5% | -50.3% | -63.3% | -55.5% | -55.6% | -36.6% | -5.8% | +4.7% | +30.7% | |
| P/FCF | 39.32 | 12.76 | — | 61.11 | 19.70 | 9.92 | — | 12.07 | 15.23 | 10.74 | — | 15.82 | 8.39 | 65.20 | — | — | 10.60 | 8.59 | — | 26.20 | 60.70 |
| — | +28.6% | — | +406.3% | +29.3% | -7.6% | — | -23.7% | +81.5% | -83.5% | — | — | -20.8% | +659.0% | — | — | -82.5% | -74.8% | — | — | — | |
| EV / EBITDA | 15.71 | 14.14 | 8.18 | 19.06 | 16.66 | 10.64 | 8.11 | 14.30 | 16.94 | 11.18 | 11.28 | 17.63 | 12.88 | 11.58 | 6.56 | 14.62 | 13.25 | 12.45 | 13.23 | 22.48 | 24.12 |
| — | +32.9% | +0.8% | +33.3% | -1.7% | -4.8% | -28.1% | -18.9% | +31.5% | -3.4% | +72.1% | +20.6% | -2.8% | -7.0% | -50.5% | -35.0% | -45.1% | -35.6% | -22.9% | -49.6% | -37.7% | |
| EV / EBIT | 58.09 | 38.44 | 27.21 | — | 1690.57 | 28.45 | 20.24 | 223.64 | 4.34 | 93.87 | 43.25 | — | — | 110.94 | 14.68 | — | 179.72 | 70.11 | 35.83 | — | — |
| — | +35.1% | +34.4% | — | +38858.9% | -69.7% | -53.2% | — | — | -15.4% | +194.6% | — | — | +58.2% | -59.0% | — | — | — | -29.0% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.5% | 58.3% | 57.3% | 39.3% | 53.4% | 46.5% | 46.6% | 38.1% | 39.3% | 47.1% | 46.2% | 36.8% | 41.3% | 46.1% | 50.0% | 41.5% | 41.5% | 47.5% | 47.3% | 41.5% | 43.1% |
| — | +25.5% | +22.9% | +3.1% | +35.8% | -1.3% | +0.8% | +3.6% | -4.8% | +2.3% | -7.6% | -11.3% | -0.6% | -3.0% | +5.8% | -0.0% | -3.8% | +1.4% | +11.7% | +24.6% | +9.0% | |
| Operating Margin | 5.3% | 8.0% | 22.4% | 1.7% | 2.4% | 6.8% | 10.1% | 0.8% | -0.5% | 9.7% | 11.0% | 1.0% | 3.9% | 5.0% | 17.6% | 2.7% | 4.9% | 11.3% | 14.4% | 3.9% | 4.6% |
| — | +16.3% | +120.8% | +111.8% | +589.2% | -29.5% | -8.1% | -18.8% | -112.3% | +93.7% | -37.2% | -64.6% | -19.3% | -55.7% | +22.5% | -29.3% | +6.0% | +20.6% | +100.3% | +141.2% | +400.7% | |
| Net Margin | -4.9% | 3.9% | 4.2% | -24.1% | -3.0% | 0.9% | 5.6% | -0.8% | 35.3% | -4.2% | 2.7% | -13.6% | -102.6% | -9.2% | 8.2% | -5.5% | -6.3% | -0.9% | 4.2% | -9.3% | -9.2% |
| — | +345.3% | -26.0% | -2976.1% | -108.5% | +121.0% | +111.5% | +94.2% | +134.4% | +54.0% | -67.6% | -149.3% | -1519.8% | -978.2% | +97.0% | +41.5% | +31.1% | +94.8% | +184.7% | +67.0% | +39.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.7% | 0.8% | 0.9% | -4.2% | -0.5% | 0.2% | 1.1% | -0.1% | 5.8% | -0.8% | 0.5% | -2.3% | -16.2% | -1.3% | 1.4% | -0.8% | -0.9% | -0.1% | 0.7% | -1.4% | -1.3% |
| — | +392.4% | -18.8% | -3174.1% | -108.6% | +120.1% | +106.5% | +94.4% | +136.1% | +36.0% | -62.6% | -196.5% | -1627.3% | -860.2% | +106.8% | +43.8% | +29.5% | +94.8% | +191.1% | +64.3% | +26.2% | |
| ROA | -1.8% | 0.4% | 0.4% | -2.1% | -0.2% | 0.1% | 0.5% | -0.1% | 2.7% | -0.4% | 0.2% | -1.0% | -7.3% | -0.6% | 0.7% | -0.4% | -0.4% | -0.1% | 0.3% | -0.6% | -0.6% |
| — | +389.3% | -18.2% | -3219.4% | -109.3% | +122.9% | +132.5% | +93.7% | +137.0% | +41.4% | -65.8% | -176.9% | -1609.2% | -878.7% | +111.4% | +43.6% | +31.7% | +94.9% | +188.6% | +65.9% | +37.5% | |
| ROIC | 1.9% | 0.8% | 2.3% | 0.1% | 0.2% | 0.6% | 0.9% | 0.1% | -0.0% | 0.8% | 0.9% | 0.1% | 0.3% | 0.3% | 1.3% | 0.2% | 0.3% | 0.8% | 1.0% | 0.2% | 0.3% |
| — | +32.5% | +155.3% | +138.1% | +663.4% | -19.0% | +4.1% | -8.2% | -113.7% | +151.6% | -32.4% | -60.4% | -15.7% | -60.5% | +28.6% | -32.7% | +4.6% | +15.3% | +106.4% | +142.0% | +398.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.61 | 0.59 | 0.61 | 0.61 | 0.60 | 0.62 | 0.69 | 0.71 | 0.67 | 0.96 | 0.95 | 0.93 | 0.96 | 0.82 | 0.80 | 0.80 | 0.87 | 0.85 | 0.81 | 0.84 | 0.82 |
| — | -4.3% | -11.2% | -13.4% | -10.7% | -35.0% | -27.3% | -23.6% | -30.7% | +16.9% | +18.3% | +15.9% | +10.1% | -3.8% | -0.1% | -4.9% | +6.1% | +11.1% | +4.7% | +16.4% | +12.1% | |
| Debt / EBITDA | 4.31 | 13.99 | 8.33 | 20.81 | 19.82 | 16.57 | 15.59 | 25.12 | 26.41 | 20.49 | 19.28 | 31.90 | 27.48 | 26.36 | 15.28 | 29.78 | 27.19 | 19.94 | 17.43 | 29.12 | 28.53 |
| — | -15.6% | -46.5% | -17.2% | -24.9% | -19.1% | -19.2% | -21.2% | -3.9% | -22.3% | +26.2% | +7.1% | +1.1% | +32.2% | -12.3% | +2.3% | -4.7% | -5.1% | -17.7% | -45.2% | -44.8% | |
| Current Ratio | 2.17 | 2.05 | 2.16 | 2.17 | 2.40 | 2.60 | 2.71 | 2.44 | 2.55 | 2.93 | 3.29 | 2.75 | 2.82 | 2.84 | 2.25 | 1.93 | 1.96 | 2.47 | 2.44 | 1.99 | 2.32 |
| — | -21.0% | -20.5% | -11.4% | -5.8% | -11.3% | -17.5% | -10.9% | -9.6% | +2.9% | +46.2% | +42.5% | +44.1% | +15.1% | -8.0% | -3.1% | -15.7% | +43.4% | +48.6% | +20.8% | +32.3% | |
| Quick Ratio | 1.08 | 1.10 | 1.12 | 1.08 | 1.23 | 1.40 | 1.46 | 1.25 | 1.31 | 1.75 | 1.96 | 1.35 | 1.48 | 1.53 | 1.24 | 1.02 | 1.12 | 1.47 | 1.41 | 1.16 | 1.30 |
| — | -21.6% | -22.9% | -13.6% | -6.5% | -20.3% | -25.6% | -7.4% | -11.4% | +14.6% | +58.3% | +31.7% | +31.8% | +3.6% | -12.6% | -11.5% | -13.8% | +48.1% | +49.9% | +30.5% | +44.9% | |
| Interest Coverage | -0.02 | 1.75 | 2.53 | -1.85 | 0.04 | 1.36 | 2.13 | 0.18 | 7.58 | 0.51 | 1.18 | -0.90 | -14.24 | 0.23 | 2.59 | -0.35 | 0.27 | 0.79 | 2.36 | -0.43 | -1.17 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ELAN stock.
Elanco Animal Health Incorporated's current P/E is -47.6x. The average P/E over the last 2 quarters is 55.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Elanco Animal Health Incorporated's current operating margin is 5.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Elanco Animal Health Incorporated's business trajectory between earnings reports.